D Mukherjee1, E Kline-Rogers, J Fang, K Munir, K A Eagle. 1. Division of Cardiology, University of Michigan, Health System, 1500 E Medical Center Drive, Ann Arbor, Michigan 48103-0311, USA. dmukherj@umich.edu
Abstract
OBJECTIVE: To assess a clinically significant interaction between cytochrome P450 3A4 (CYP3A4) metabolised statin and clopidogrel. DESIGN: Prospective single centre cohort study. SETTING: Academic teaching hospital in the USA. PATIENTS: 1651 patients presenting with acute coronary syndromes between January 1999 and February 2003 were studied. Data on baseline demographics, co-morbidities, and in-hospital management were collected. MAIN OUTCOME MEASURE: Association of CYP3A4 metabolised statin and clopidogrel use with in-hospital and six month mortality. The impact of the combined use of a CYP3A4 statin and clopidogrel on six month mortality and major adverse cardiac events was analysed by a risk adjusted logistic regression model. RESULTS: The odds ratios for six month mortality were: for CYP3A4 statin, 0.43 (95% confidence interval (CI) 0.27 to 0.71, p = 0.0009); for CYP3A4 statin plus clopidogrel, 0.36 (95% CI 0.23 to 0.60, p < 0.001); for non-CYP3A4 statin, 0.22 (95% CI 0.08 to 0.59, p = 0.002); and for non-CYP3A4 statin plus clopidogrel, 0.22 (95% CI 0.06 to 0.75, p = 0.016). CONCLUSIONS: Use of a combination of a CYP3A4 statin plus clopidogrel was associated with lower six month mortality and morbidity in patients with acute coronary syndromes. There was no significant difference in clinical benefit between a CYP3A4 statin and a non-CYP3A4 statin when used in conjunction with clopidogrel. This suggests that the proposed interaction is probably an ex vivo phenomenon and may not be clinically relevant.
OBJECTIVE: To assess a clinically significant interaction between cytochrome P450 3A4 (CYP3A4) metabolised statin and clopidogrel. DESIGN: Prospective single centre cohort study. SETTING: Academic teaching hospital in the USA. PATIENTS: 1651 patients presenting with acute coronary syndromes between January 1999 and February 2003 were studied. Data on baseline demographics, co-morbidities, and in-hospital management were collected. MAIN OUTCOME MEASURE: Association of CYP3A4 metabolised statin and clopidogrel use with in-hospital and six month mortality. The impact of the combined use of a CYP3A4 statin and clopidogrel on six month mortality and major adverse cardiac events was analysed by a risk adjusted logistic regression model. RESULTS: The odds ratios for six month mortality were: for CYP3A4 statin, 0.43 (95% confidence interval (CI) 0.27 to 0.71, p = 0.0009); for CYP3A4 statin plus clopidogrel, 0.36 (95% CI 0.23 to 0.60, p < 0.001); for non-CYP3A4 statin, 0.22 (95% CI 0.08 to 0.59, p = 0.002); and for non-CYP3A4 statin plus clopidogrel, 0.22 (95% CI 0.06 to 0.75, p = 0.016). CONCLUSIONS: Use of a combination of a CYP3A4 statin plus clopidogrel was associated with lower six month mortality and morbidity in patients with acute coronary syndromes. There was no significant difference in clinical benefit between a CYP3A4 statin and a non-CYP3A4 statin when used in conjunction with clopidogrel. This suggests that the proposed interaction is probably an ex vivo phenomenon and may not be clinically relevant.
Authors: C P Cannon; A Battler; R G Brindis; J L Cox; S G Ellis; N R Every; J T Flaherty; R A Harrington; H M Krumholz; M L Simoons; F J Van De Werf; W S Weintraub; K R Mitchell; S L Morrisson; R G Brindis; H V Anderson; D S Cannom; W R Chitwood; J E Cigarroa; R L Collins-Nakai; S G Ellis; R J Gibbons; F L Grover; P A Heidenreich; B K Khandheria; S B Knoebel; H L Krumholz; D J Malenka; D B Mark; C R Mckay; E R Passamani; M J Radford; R N Riner; J B Schwartz; R E Shaw; R J Shemin; D B Van Fossen; E D Verrier; M W Watkins; D R Phoubandith; T Furnelli Journal: J Am Coll Cardiol Date: 2001-12 Impact factor: 24.094
Authors: Wei C Lau; Lucy A Waskell; Paul B Watkins; Charlene J Neer; Kevin Horowitz; Amy S Hopp; Alan R Tait; David G M Carville; Kirk E Guyer; Eric R Bates Journal: Circulation Date: 2003-01-07 Impact factor: 29.690
Authors: Eugene Braunwald; Elliott M Antman; John W Beasley; Robert M Califf; Melvin D Cheitlin; Judith S Hochman; Robert H Jones; Dean Kereiakes; Joel Kupersmith; Thomas N Levin; Carl J Pepine; John W Schaeffer; Earl E Smith; David E Steward; Pierre Theroux; Raymond J Gibbons; Joseph S Alpert; David P Faxon; Valentin Fuster; Gabriel Gregoratos; Loren F Hiratzka; Alice K Jacobs; Sidney C Smith Journal: Circulation Date: 2002-10-01 Impact factor: 29.690
Authors: Jacqueline Saw; Steven R Steinhubl; Peter B Berger; Dean J Kereiakes; Victor L Serebruany; Danielle Brennan; Eric J Topol Journal: Circulation Date: 2003-08-18 Impact factor: 29.690
Authors: Anna Toso; Stefano De Servi; Mario Leoncini; Dominick J Angiolillo; Paolo Calabrò; Federico Piscione; Marco Cattaneo; Diego Maffeo; Antonio Bartorelli; Cataldo Palmieri; Marco De Carlo; Davide Capodanno; Philippe Genereux; Francesco Bellandi; Chiara Barozzi; Luciana Tomasi; Diego Della Riva; Tullio Palmerini Journal: J Thromb Thrombolysis Date: 2017-10 Impact factor: 2.300
Authors: Morten Schmidt; Martin B Johansen; Michael Maeng; Anne Kaltoft; Lisette O Jensen; Hans-Henrik Tilsted; Hans E Bøtker; John A Baron; Henrik Toft Sørensen Journal: Br J Clin Pharmacol Date: 2012-07 Impact factor: 4.335
Authors: Goeng Bae Kim; Jeong Kyung Kim; Sul Park; Jae Jin Jeong; Hyung Sik Yoon; Sang Hun Ko; Jae Ee Ko; Soo Jin Park; Seon Woo Nam; Jae Hwan Lee; Min Soo Hyon Journal: Korean Circ J Date: 2011-01-31 Impact factor: 3.243